Compare Moderna, Inc. (MRNA) vs Stitch Fix Inc (SFIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Stitch Fix Inc — how do they compare? Moderna, Inc. trades at $60.59 (market cap $23.88B), while Stitch Fix Inc trades at $3.79 (market cap $530.37M). The key difference: Moderna, Inc. is far larger — about 45× Stitch Fix Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Stitch Fix Inc nearer its low. Which is the better fit depends on your goals.
| MRNA | SFIX | |
|---|---|---|
Market Cap | $23.88B | $530.37M |
Sector | Health | Consumer Cyclical |
52-Week High | $81.80 | $5.83 |
52-Week Low | $22.36 | $3.06 |
Enterprise Value | $20.03B | $418.08M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) stock trades at $59.17, up 9.86% recently, with a bullish technical signal and strong institutional buying interest. The company's Q2 2026 earnings beat expectations, and the FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50+ marks a key post-pandemic milestone. However, fundamentals show declining revenue from $18.9B in 2022 to $1.9B in 2025 and persistent net losses, with a negative net income margin of -142.58% in 2025.
The outlook hinges on pipeline execution; while new vaccine approvals and cost-cutting efforts offer growth potential, the stock faces risks from high valuation multiples and ongoing profitability challenges. Analyst consensus is cautious with a $54.33 price target below the current price, reflecting mixed sentiment amid transitional phase uncertainties.
Stitch Fix (SFIX) trades at $4.20, up 4.22% today, showing stabilization after a multi-year decline. The stock is technically bullish with strong moving average signals, while fundamentals reflect a turnaround with revenue stabilizing at $1.27B and net losses narrowing to -$28.74M in 2025. Recent news highlights AI-driven personalization gains and a debt-free balance sheet, supporting a potential recovery narrative.
The outlook hinges on execution of the turnaround; improving client growth and cost controls offer upside, but persistent losses and consumer spending pressures pose risks. Analysts are cautious with a $4.75 price target and 63.6% hold rating, suggesting the stock may be fairly valued amid its recovery phase.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Stitch Fix Inc
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →
